PsyCan - Newsroom

Press Releases

Press Release — Aug 09, 2024

PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application

Read

Press Release — Apr 02, 2024

PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta

Read

Press Release — Nov 08, 2023

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy

Read

Press Release — Oct 03, 2023

The Future of Psychedelic Access in Canada: PsyCan Releases White Paper Reviewing Regulatory Options for Psychedelics

Read

Press Release — Jun 30, 2023

Canadian Psychedelic Medicine and Therapy Sector Welcomes Initial Federal Investment in Psychedelic Medical Research

Read

Press Release — Oct 06, 2022

Alberta government must engage with psychedelic sector for regulatory success

Read

Press Release — Sept 21, 2022

Canadian Psychedelics Industry Tells Policy Makers: Make Room for Healthcare Innovation

Read

Press Release — Aug 19, 2022

Globe and Mail: 'Fundamental value' in psychedelics remains despite market downturn

Read

Press Release — Jun 03, 2022

PSYCHEDELICS CANADA APPLAUDS HEALTH CANADA AND BC GOVERNMENT DECISION TO DECRIMINALIZE POSESSION OF SMALL AMOUNTS OF DRUGS

Read

Press Release — May 27, 2022

PSYCHEDELICS CANADA ANNOUNCES THE LAUNCH OF THE FIRST NATIONAL TRADE ASSOCIATION FOR LEGAL PSYCHEDELICS COMPANIES

Read

Members in The News

News Item — Jul 17, 2023

Empower Psychedelics preparing for clinical trials through the Special Access Program

Read

News Item — Jul 14, 2023

Check out MAPS Canada's ongoing seminars on fascinating issues related to psychedelic medicine and therapy through their #SchoolofPsychedelics.

Read

News Item — Apr 11, 2023

Filament Health And PharmAla Biotech Announce Release Of GMP MDMA Capsules

Read

News Item — Jul 26, 2022

Psyched Wellness Announces Findings From an Ongoing Study With the National Research Council of Canada

Read

News Item — Mar 28, 2023

Psyched Wellness Is Pleased to Announce Recent Neurobehavioral Study Evaluating Efficacy and Safety of AME-1

Read

News Item — Jul 28, 2022

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project

Read

News Item — Dec 04, 2022

A Canadian psychedelic drug company has created medical grade ayahuasca

Read

News Item — Feb 14, 2023

Filament Health Announces Second Psilocybin Supply Agreement With The Centre For Addiction And Mental Health

Read

News Item — Mar 15, 2023

Filament Health Announces FDA Approval Of Phase II Clinical Trial Studying Psilocybin For Methamphetamine Use Disorder

Read

News Item — Mar 24, 2023

Inside the Vancouver lab where scientists (legally) grow magic mushrooms

Read

News Item — Oct 11, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Read

News Item — Oct 06, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Read

News Item — Oct 26, 2022

SABI Mind Launches Equitable Access Program

Read

News Item — Feb 01, 2023

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Read

News Item — Mar 02, 2023

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Read

News Item — Sept 01, 2022

SABI Mind Introduces Specialized Ketamine Therapy for Chronic Pain

Read

News Item — Feb 01, 2023

First Alberta Clinical Site for Study of Psychedelic-Assisted Treatment for Alcohol Use Disorder Approved

Read

News Item — Oct 05, 2022

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

Read

News Item — May 20, 2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

Read

News Item — May 16, 2022

Ketamine Clinic in Kelowna

Read

News Item — May 12, 2022

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Read

News Item — May 12, 2022

SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies

Read

News Item — May 12, 2022

Psygen Receives Dealer's Licence from Health Canada

Read

News Item — May 12, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Read

Newsroom

Press Releases

PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application

PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy

The Future of Psychedelic Access in Canada: PsyCan Releases White Paper Reviewing Regulatory Options for Psychedelics

Canadian Psychedelic Medicine and Therapy Sector Welcomes Initial Federal Investment in Psychedelic Medical Research

Alberta government must engage with psychedelic sector for regulatory success

Canadian Psychedelics Industry Tells Policy Makers: Make Room for Healthcare Innovation

Globe and Mail: 'Fundamental value' in psychedelics remains despite market downturn

PSYCHEDELICS CANADA APPLAUDS HEALTH CANADA AND BC GOVERNMENT DECISION TO DECRIMINALIZE POSESSION OF SMALL AMOUNTS OF DRUGS

PSYCHEDELICS CANADA ANNOUNCES THE LAUNCH OF THE FIRST NATIONAL TRADE ASSOCIATION FOR LEGAL PSYCHEDELICS COMPANIES

Members in The News

Empower Psychedelics preparing for clinical trials through the Special Access Program

Check out MAPS Canada's ongoing seminars on fascinating issues related to psychedelic medicine and therapy through their #SchoolofPsychedelics.

Filament Health And PharmAla Biotech Announce Release Of GMP MDMA Capsules

Psyched Wellness Announces Findings From an Ongoing Study With the National Research Council of Canada

Psyched Wellness Is Pleased to Announce Recent Neurobehavioral Study Evaluating Efficacy and Safety of AME-1

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project

A Canadian psychedelic drug company has created medical grade ayahuasca

Filament Health Announces Second Psilocybin Supply Agreement With The Centre For Addiction And Mental Health

Filament Health Announces FDA Approval Of Phase II Clinical Trial Studying Psilocybin For Methamphetamine Use Disorder

Inside the Vancouver lab where scientists (legally) grow magic mushrooms

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

SABI Mind Launches Equitable Access Program

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

SABI Mind Introduces Specialized Ketamine Therapy for Chronic Pain

First Alberta Clinical Site for Study of Psychedelic-Assisted Treatment for Alcohol Use Disorder Approved

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

Ketamine Clinic in Kelowna

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies

Psygen Receives Dealer's Licence from Health Canada

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Media Inquiries

Stay in the loop